4.7 Article

OMIXCARE: OMICS technologies solved about 33% of the patients with heterogeneous rare neuro-developmental disorders and negative exome sequencing results and identified 13% additional candidate variants

Journal

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fcell.2022.1021785

Keywords

undiagnosed neurodevelopmental diseases; genome sequencing; transcriptome sequencing; DNA methylation analysis; translational research

Funding

  1. Dijon University Hospital
  2. ISITE-BFC (PIA ANR)
  3. European Union through the FEDER programs (PERSONALISE)
  4. Burgundy-Franche-Compte regional council (INTEGRA)
  5. France Genomique National infrastructure
  6. Laboratory of Excellence GENMED (Medical Genomics) [ANR-10-INBS-09]
  7. [ANR-10-LABX-0013]

Ask authors/readers for more resources

This study utilized multiple molecular analysis techniques, including genome sequencing, RNA sequencing, and DNA methylation analysis, to diagnose cases of rare neurodevelopmental disorders with negative exome sequencing results. The study found that integrating these techniques can solve some cases and identify potential candidate genes.
Purpose: Patients with rare or ultra-rare genetic diseases, which affect 350 million people worldwide, may experience a diagnostic odyssey. High-throughput sequencing leads to an etiological diagnosis in up to 50% of individuals with heterogeneous neurodevelopmental or malformation disorders. There is a growing interest in additional omics technologies in translational research settings to examine the remaining unsolved cases. Methods: We gathered 30 individuals with malformation syndromes and/or severe neurodevelopmental disorders with negative trio exome sequencing and array comparative genomic hybridization results through a multicenter project. We applied short-read genome sequencing, total RNA sequencing, and DNA methylation analysis, in that order, as complementary translational research tools for a molecular diagnosis. Results: The cohort was mainly composed of pediatric individuals with a median age of 13.7 years (4 years and 6 months to 35 years and 1 month). Genome sequencing alone identified at least one variant with a high level of evidence of pathogenicity in 8/30 individuals (26.7%) and at least a candidate disease-causing variant in 7/30 other individuals (23.3%). RNA-seq data in 23 individuals allowed two additional individuals (8.7%) to be diagnosed, confirming the implication of two pathogenic variants (8.7%), and excluding one candidate variant (4.3%). Finally, DNA methylation analysis confirmed one diagnosis identified by genome sequencing (Kabuki syndrome) and identified an episignature compatible with a BAFopathy in a patient with a clinical diagnosis of Coffin-Siris with negative genome and RNA-seq results in blood. Conclusion: Overall, our integrated genome, transcriptome, and DNA methylation analysis solved 10/30 (33.3%) cases and identified a strong candidate gene in 4/30 (13.3%) of the patients with rare neurodevelopmental disorders and negative exome sequencing results.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available